< Back to previous page

Project

VyCAP single cell isolation platform for high-quality single-cell analysis

This application concerns the acquisition of VyCAP’s single-cell platform for the isolation of (rare) single cells with high recoveries and subsequent high-quality RNA and DNA analysis or cell culturing. The system is compatible with all single-cell downstream analysis technologies and supports a wide range of applications, including analysis of circulating tumor cells, single cell secretion profiles and monoclonal cell line selection. The equipment will broaden the research capabilities of the applicants in several projects, including immunoprofiling, monoclonal antibody generation for therapeutic and diagnostic purposes and cell line selection, while associated costs will decrease. In addition, because of its broad applicability, it will be an added value in multiple research projects and several research groups already expressed their interest to include it in their (future) work.
Date:1 Jan 2021 →  31 Dec 2022
Keywords:Single-cell analysis, Monoclonal antibody development, Cell line selection
Disciplines:Applied immunology, Drug discovery and development not elsewhere classified, General diagnostics, Cancer biology